Our monthly subscription fees have changed recently. Please see the latest information here.
From 11 April, the FX fee charged when trading stocks priced in USD or EUR will change to 0.99% on our Basic plan, 0.59% on our Standard plan, and 0.39% on our Plus plan.
From May, monthly subscription fees will change to £5.99 per month for our Standard plan and £11.99 per month for our Plus plan.
Everything in Basic, plus:
Everything in Standard, plus:
More of what you want.
We’ve got a HUGE batch of new additions this week, including our first major Plus universe expansion, so we’ve got a bit more for you in this week’s blog!
Exclusively for Plus
We’re really excited about the first big batch of stocks of over 200 we’ve added for our early Plus members. Highlights include:
Hotels to horse-racing and a few more US stocks in between
As we promised last week, we’re continuing to expand the list of stocks available to everyone. We’ve got an eclectic group this week, with some well-known brands and dominant industry players, like:
Insurance and investment managers
There are a lot of financial institutions in this week’s addition, including some big names in consumer finance and investment management.
There’s a range of biotechnology and biopharmaceutical companies that we’ve added this week, developing cutting edge therapies and medical devices.
Lots of ADRs 🇨🇳
We’ve also been sure to add American Depository Receipts (ADRs) for some major companies based outside of the UK and US.
Don’t forget the SPACs!
Last but not least, we’ve added a few more SPACs - all of which have already identified a target to merge with.
Not sure what a SPAC is? Why not check out a post from earlier in the year?
Plus members will also see a brand new Collection for SPACs on their app.
Join the discussion on the forum and see the full list of stocks.
This should not be read as personal investment advice and individual investors should make their own decisions or seek independent advice. This article has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is considered a marketing communication.
When you invest, your capital is at risk. The value of your portfolio can go down as well as up and you may get back less than you invest.
Freetrade is a trading name of Freetrade Limited, which is a member firm of the London Stock Exchange and is authorised and regulated by the Financial Conduct Authority. Registered in England and Wales (no. 09797821).
The views expressed above are those of community members and do not reflect the views of Freetrade. It is not investment advice and we always encourage you to do your own research.